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MEETING SUMMARY
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What’s the Difference Compared with the United States
and Europe? Results of the Second Asia Pacific Lung
Cancer Conference
Yi-long Wu, FACS, Qing Zhou, MD, PhD
(J Thorac Oncol. 2007;2: 574–576)
The Second Asia Pacific Lung Cancer Conference(APLCC), hosted by Guangdong Provincial People’s
Hospital and the Lung Cancer Research Institute of Guang-
dong Province under the auspices of the Chinese Society of
Lung Cancer (CSLC), Asia Pacific Lung Cancer Group
(APLCG), and International Association for the Study of
Lung Cancer (IASLC), was held in Guangzhou, China, De-
cember 1-3, 2006. The APLCG has conducted conferences
biennially to promote academic communication and cooper-
ation between the Asia-Pacific region and international soci-
eties. The first APLCC was held in 2004 in Chiang Mai,
Thailand. The theme of the second APLCC was “Lung cancer
management in the Asia-Pacific Region: what’s the differ-
ence compared with the United States and Europe?” Nearly
400 attendees from nine Asian-Pacific countries, including
Malaysia, Singapore, Thailand, Indonesia, India, Korea, Ja-
pan, Australia, and China, gathered in Guangzhou, a beautiful
city in Southern China. Of particular note, some experts in
lung cancer from the United States, Germany, Italy, Japan,
and Australia also attended this conference and shared their
up-to-date experiences in lung cancer research. Among these
experts were Professor Paul Bunn, executive director of
IASLC, from the University of Colorado Health Sciences
Center, Colorado; Professor Giorgio Scagliotti from the Uni-
versity of Turin, S. Luigi Hospital, Italy; Professor Christian
Manegold from the University of Heidelberg, Germany; and
Professor Nagahiro Saijo, the president elect of IASLC, from
the National Cancer Center, Chiba, Japan. Attendees and
experts discussed their latest research findings from all over
the world, making this conference truly international.
The 22 presentations discussed improvements in sur-
gery, chemotherapy, radiotherapy, targeted therapy, immuno-
therapy, genomics, and proteomics of lung cancer. All the
presentations focused on the conference theme: “Lung cancer
management in the Asia-Pacific Region: what’s the differ-
ence compared with the United States and Europe?”
GLOBAL TRENDS IN INCIDENCE, MORTALITY,
EARLY DETECTION, AND PREVENTION
Professor Paul Bunn from the University of Colorado,
Professor Harvey I. Pass from New York, and Professor
Sumitra Thongprasert from Thailand reported on the epide-
miological global trend of lung cancer. Tobacco is still the
leading cause of lung cancer worldwide and is a particular
problem in the United States. Globally, 85% of lung cancers
in men and 47% in women were caused by tobacco. In the
United States, 92% of lung cancers in men and 80% in
women were caused by tobacco, whereas the percentages in
Europe were 92% and 72%, respectively. More women de-
veloped lung cancer because of smoking in the United States
than in any other area. The worldwide incidence of lung
cancer is also increasing. The number of new cases in the
United States in 2006 was 174,470, making lung cancer the
second most common malignant tumor. It caused 162,460
deaths, the highest for any malignant tumor. In China in
2005, there were 497,908 new cases and 428,936 deaths, both
the highest for any malignant tumor. In China, the age-
standardized incidence rate and age-standardized mortality
rate adjusted for the world standard population are both
higher than the average levels worldwide.
In the United States, the incidence rate for squamous
cell and small cell lung cancers began decreasing among men
in the mid-1980s, but a decline in the incidence of adenocar-
cinoma among men was not observed until 5 to 10 years later.
Similarly, the incidence rates of squamous cell, large cell, and
small cell lung cancers among women leveled off or started to
decrease, but the incidence of adenocarcinoma continued to
increase. As a result of these changes, adenocarcinoma has
become the most common type of lung cancer in the United
States during the past decades. In Asia, similar changes have
also been seen, as adenocarcinoma has also become the most
common type of lung cancer in Asia, particularly in women.
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Adenocarcinoma tumorigenesis in women might be attribut-
able to factors other than smoking, such as cooking oils,
indoor coal smoke, differences in metabolic enzyme cyto-
chrome P-450 2A6, and dietary deficiencies in antioxidants.
The 5-year survival rate among patients with lung
cancer was 15% in the United States, 10% in Europe, and
8.9% in developing countries. Early detection and prevention
are important for improving survival. In the United States,
pooled analyses strongly suggest that computed tomographic
(CT) screening is effective for early detection, but the cost of
screening is problematic. Studies investigating early detec-
tion, such as Chiba, ELCAP, Mayo, Muenster, and Milan, are
ongoing.
TARGETED THERAPY
Epidermal growth factor receptor tyrosine kinase inhib-
itor (EGFR-TKI) was a focus of this conference. In the ISEL
trial, the median survival did not differ significantly between
gefitinib and placebo groups in the overall population, but
gefitinib was shown to increase survival among patients of
Asian origin. In the BR21 trial of erlotinib, a survival benefit
could be seen in patients of both Asian and non-Asian origin.
Because of the differing results of the clinical trials for the
two agents, erlotinib, but not gefitinib, can be used as stan-
dard second-line therapy for non-small cell ling cancer
(NSCLC) in the United States and Europe, whereas both can
be used as standard second-line therapy in Asia.
The predictive factors for response and overall survival
of patients receiving EGFR-TKIs were another focus of this
conference. Professor Tony Mok from Hong Kong, Professor
Keunchil Park from Korea, and Professor Shun Lu from
mainland China showed data from Asian countries. Pathol-
ogy, gender, and smoking status were all important clinical
factors. Using univariate analysis, it was uniformly consid-
ered that pathology and smoking status were the main pre-
dictive factors for response; however, using multivariate
analysis, there were different results for different countries.
As to the predictive factors for overall survival, performance
status was considered to be an effective factor, but there was
disagreement about the significance of gender, pathology, and
smoking status. Since 2004, many studies have tried to
demonstrate the effect of EGFR expression, EGFR gene
amplification, and gene mutations in predicting response and
overall survival. Nevertheless, there is as yet no definitive
viewpoint about their effects because most of these studies
used small sample numbers and were retrospective. The use
of biomarkers might make more sense in non-predominant
patients, such as those who are male, have squamous carci-
noma, and are smokers.
Because of the marvelous effects of EGFR-TKIs in the
second-line setting in Asia, several multicenter clinical trails,
such as IPASS, FAST-ACT, TOPICAL, and SATURN, are
ongoing to confirm the effect of EGFR-TKIs in the first-line
setting.
MANAGEMENT OF EARLY-STAGE NSCLC
Professor Yi-Long Wu reported 5-year survival rates
according to the stage of lung cancer in China; the results
were similar to those from Mountain in the United States.
Regarding surgical therapy for early-stage NSCLC, Professor
Wu reported the failure of a treatment model after performing
surgery on 471 patients with NSCLC: 3.8% (18/471) of the
failures resulted from recurrence and 26.5% (125/471) from
metastasis. Thus, distance metastasis is still a major cause of
treatment failure, suggesting that adjuvant and neo-adjuvant
chemotherapy are still very meaningful for complete resec-
tion of NSCLC. A clinical trial in China focusing on adjuvant
chemotherapy for NSCLC (CSLC 0201-TAX-210) showed a
significant difference in the disease-free survival between
-tubulin-positive and -negative groups. The study empha-
sized again the importance of tailored therapy for both early-
stage and advanced NSCLC.
Professor Hisao Asamura from the National Cancer
Center Hospital, Japan, reported on the management of pa-
tients with ground glass opacities (GGOs). GGOs smaller
than 15 mm in diameter or non-solid GGOs can be carefully
monitored by high-resolution CT, but the part-solid GGOs or
GGOs larger than 15 mm in diameter require surgical inter-
vention. The 5-year survival was 95% to 100%.
The presentation by Professor Wilfried Eberhardt from the
West German Cancer Centre, University of Duisburg-Essen,
summarized the results of some famous clinical trials, such as
IALT, BR10, GALGB9633, ANITA, and SWOG9900, which
investigated adjuvant and neo-adjuvant chemotherapy for com-
plete resection of NSCLC in the United States and Europe. The
results showed that it is particularly important to compare the
effects of adjuvant and neo-adjuvant chemotherapy. A multi-
center randomized clinical trial initiated by Professor Yi-Long
Wu is ongoing in China (CSLC0501-TAX623-NCT00321334).
In this trial, the adjuvant and neo-adjuvant chemotherapy regi-
mens are both taxotere: 75 mg/m2, d1, CBP (AUC 5), d1, q3w,
three cycles. The result of this clinical trial will provide new
guidance for the practice of multidisciplinary synthetic therapy
of early-stage NSCLC.
CHEMOTHERAPY
Professor Fred R. Hirsch from the Cancer Center of
Colorado University introduced, in detail, the study ECOG
E4599 of bevacizumab in advanced NSCLC (non-squamous).
The addition of bevacizumab to carbo/paclitaxel increased
progression-free survival and overall survival among patients
with advanced non-squamous NSCLC and no brain metasta-
sis. The results have raised new questions. Should carbo/
paclitaxel/bevacizumab be the standard regimen for such
patients? Should it be the control arm for all randomized
trials? Should patients with squamous carcinoma, brain me-
tastasis, and anticoagulants receive this therapy before addi-
tional studies are complete? Should this regimen be used at
earlier stages? To answer these questions, important ongoing
trials with bevacizumab (California Cancer Consortium study
and industry-sponsored study) are exploring its safety in
squamous cell carcinoma and in patients with treated brain
metastasis (industry-sponsored study) and are evaluating its
efficacy and safety for locally advanced NSCLC (cooperative
groups). Despite these concerns, carbo/paclitaxel/bevaci-
zumab has been listed in Europe as the standard regimen for
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patients with advanced non-squamous NSCLC and no brain
metastasis. However, in most Asian countries, including
China, there have been very few clinical trials with bevaci-
zumab, and platinum-based doublet chemotherapy is still
standard therapy for advanced NSCLC.
Tailored chemotherapy based on molecular markers
and individual pharmacokinetics may represent the future for
NSCLC treatment in both the United States and Europe, as
well as in Asia. Some ongoing clinical trials for advanced
NSCLC are based on the expression of genes such as ERCC1,
RRM1, and -tubulin. Differences in pharmacokinetics
among races may also influence the outcome of clinical drug
trials. For example, differences in the outcome of irinotecan/
cisplatin (IP) versus etoposide/cisplatin (EP) chemotherapy
for extensive SCLC were found between Japan and North
America. EP remains the current standard of care for exten-
sive-disease SCLC in the United States and Europe, whereas
IP is more acceptable in Japan and China.
RADIOTHERAPY
Professor David Ball from the Peter MacCallum Cancer
Centre of Australia and Professor Guo-Liang Jiang from the
Shanghai Fudan University Cancer Hospital of China re-
ported recent developments in radiotherapy for NSCLC. In
the United States, Europe, and Asia, new techniques are
being developed to improve the accuracy and reduce the
toxicity associated with radiotherapy. Fluro-deoxy-glucose
(FDG) positron emission tomography (PET) scanning im-
proves the mapping of the disease, allowing doctors to select
those patients most suitable for radiotherapy. Hybrid PET/CT
can more accurately define the target and can track the target
during treatment. Standardized uptake value aids in assessing
the response to radiotherapy. Three-dimensional conformal
radiotherapy, or stereotactic radiotherapy, has been effective
in locally advanced NSCLC and has also become a good
alternative for treating medically inoperable stage I NSCLC.
Intensity modulated radiation therapy, another advanced
technique in radiotherapy for NSCLC, has a dosimetric ad-
vantage over three-dimensional conformal radiotherapy be-
cause it delivers a lower dose to normal lung and heart.
OTHER TOPICS
Other topics discussed at the second APLCC focused
on immunotherapy for lung cancer (David Carbone, Vander-
bilt University Cancer Center), quality of life and cost-
effectiveness in the clinical practice of lung cancer treatment
(Richard Gralla, New York Lung Cancer Alliance, New
York), genomics and proteomics of lung cancer (Giorgio
Scagliotti, University of Turin, Italy, and Nagahiro Saijo,
National Cancer Center, Chiba, Japan), and translational
research in lung cancer (Purvish Parikh, Tata Memorial
Hospital, India). These presentations provided important new
information.
We had an exciting and provocative conference in
Guangzhou, China. This conference promoted academic
communication and cooperation between the Asia-Pacific
region and international societies, aiding progress in lung
cancer research worldwide.
Finally, we gratefully acknowledge the International
Association for the Study of Lung Cancer (IASLC), the Asia
Pacific Lung Cancer Group (APLCG), the Chinese Society of
Lung Cancer (CSLC), Bristol-Myers Squibb Company, Eli
Lilly Asia Inc., Shanghai Roche Pharmaceuticals Ltd., Astra-
Zeneca China Ltd., and all other contributing companies for
their sponsorship of this conference.
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